Update on the Combination of Myo-Inositol / D-Chiro-Inositol for the Treatment of Polycystic Ovary Syndrome
Lete I, Martinez A, Lasaga I, Centurion E, Vesga A
Published in Gynecological Endocrinology
Methodology
Review of clinical evidence for myo-inositol and D-chiro-inositol combinations, focusing on the 40:1 physiological plasma ratio.
Key Findings
Combination products at the 40:1 ratio improved menstrual regularity and metabolic parameters, while high-dose isolated D-chiro-inositol has been associated with reduced oocyte quality (the "D-chiro-inositol paradox").
Conclusions
Ratio and dose matter: isolated high-dose D-chiro-inositol may be counterproductive for ovarian function.
Limitations
Narrative review; industry involvement common in this literature; few head-to-head trials.
Supplements Studied
High-dose isolated D-chiro-inositol has been associated with reduced oocyte quality, the so-called D-chiro-inositol paradox.
Combination products at the 40:1 ratio improved menstrual regularity and metabolic parameters, while high-dose isolated D-chiro-inositol has been associated with reduced oocyte quality (the "D-chiro-inositol paradox").
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.